CHO-GLP-1 Luciferase Reporter Cell Line
Purpose-built for potency testing of GLP-1 receptor agonists and already used in regulatory filings for multiple marketed GLP-1 drugs.
Equivalent quality at a substantially lower cost.
Regulatory-proven
Supports filings of multiple marketed GLP-1 products in China and abroad.
Equivalent quality
Same quality standard as comparable products; every WCB lot fully QC-released.
Significant cost savings
Priced well below comparable imported lines, with a low-cost commercial license.
From receptor binding to a luminescent readout
- 01GLP-1R agonistSample or reference
- 02Receptor activationGLP-1R
- 03Gαs / ACAdenylyl cyclase
- 04cAMP riseSecond messenger
- 05CRE-driven transcriptionReporter gene
- 06Luminescence readoutLuciferase
Luminescence is dose-dependent on agonist activity; relative potency is calculated against a reference standard.
Built for release testing and regulatory filings
Filing-ready
Assay design aligned with ICH Q2(R2)/Q14, USP <1032>/<1033> and ChP bioassay requirements.
One line, broad coverage
Measures GLP-1R activity of both mono- and multi-agonist molecules.
Documentation package
Origin, construction and banking records plus COA for CTD inclusion and agency queries.
Affordable commercial license
Low licensing fee and clear terms for commercial release and filing use.
Fast and scalable
Simple same-day workflow; compatible with 96/384-well plates and automation.
Product + service
Bundle with Quickgene method development, validation and testing services.
Every working cell bank lot is fully QC-released
| Item | Specification / result |
|---|---|
| Product | CHO-GLP-1 reporter cell line (WCB) |
| Cat. No. | T82011 |
| Host cell | CHO |
| Readout | Luciferase luminescence |
| Size | 1 vial, 2 × 10⁶ cells |
| Storage | Liquid nitrogen |
| Max. passage | P57 |
| Mycoplasma | Negative |
| Bacteria | Negative |
| Fungi | Negative |
| Cell viability | ≥ 90% confluence on day 3 post-thaw — Pass |
Product information is subject to the current lot COA.
Suitable molecules and use cases
Suitable molecules
- Semaglutide
- Liraglutide
- Dulaglutide
- Exenatide
- Tirzepatide
- Retatrutide
- Other GLP-1R agonists
Use cases
- API and drug product release testing
- Stability studies
- Generic / biosimilar comparability studies
- Bioassay development, validation and transfer
- Process development and candidate screening
Documentation, services and supply
Regulatory support
Cell origin and construction information, banking records, lot COA and support for agency queries.
Method services
- Platform-method testing
- 10 WDPlatform-method testing
- Routine development + validation
- 20 WDRoutine development + validation
From sample receipt, using Quickgene analytical services.
Cell-based bioassay serviceLicense and supply
Low-cost commercial license; lot-based WCB supply with cold-chain shipping.
Peptide bioassay experience behind the product
Peptide bioassay expertise
Analytical and bioassay support for GLP-1 peptide programs filed in China, the US, the EU and Australia.
Same quality, lower cost
Equivalent quality at a substantially lower price, reducing total program cost.
Common questions
Which molecules can the CHO-GLP-1 cell line test?
It measures GLP-1R activity of mono- and multi-agonist molecules, including semaglutide, liraglutide, dulaglutide, exenatide, tirzepatide, retatrutide and other GLP-1R agonists.
Can it be used for commercial release testing and regulatory filings?
Yes. A low-cost commercial license with clear terms covers commercial release and filing use, and the cell line has already been used in filings for multiple marketed GLP-1 drugs.
What documentation is provided for a filing?
Cell origin and construction information, banking records and the lot COA for CTD inclusion, plus technical support for agency queries.
How is the cell line supplied and stored?
As a working cell bank: 1 vial of 2 × 10⁶ cells, stored in liquid nitrogen and shipped lot-based with cold-chain transport. Maximum passage is P57.
Can Quickgene develop and validate the assay for us?
Yes. Platform-method testing takes 10 working days and routine method development plus validation 20 working days, counted from sample receipt.
Request a quote and technical datasheet
Pricing, licensing options and the documentation package
Contact us for pricing, licensing options and the regulatory documentation package.
For research and pharmaceutical QC testing only. Not for human or diagnostic use. Product information subject to the current lot COA.